Company Filing History:
Years Active: 2023
Title: Oh-Byung Kwon: Innovator in Long-Acting Insulin Analogues
Introduction
Oh-Byung Kwon is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of diabetes treatment through his innovative work on insulin analogues. His research focuses on improving the efficacy and convenience of insulin administration for diabetic patients.
Latest Patents
Oh-Byung Kwon holds a patent for "Long-acting insulin analogues and derivatives thereof." This invention relates to long-acting insulin analogues that have an increased in vivo half-life. The innovation involves substituting the amino acid at position 22 of the B-chain of native insulin and making additional substitutions in the A-chain or B-chain. Furthermore, the patent includes long-acting insulin analogue derivatives that have an albumin-binding domain fused to them, resulting in a significantly increased in vivo half-life. This advancement provides greater convenience for diabetic patients who self-administer insulin by injection.
Career Highlights
Oh-Byung Kwon is associated with Daewoong Pharmaceutical Co., Ltd., where he continues to develop groundbreaking solutions in the pharmaceutical industry. His work has been instrumental in enhancing the quality of life for individuals managing diabetes.
Collaborations
He has collaborated with notable colleagues, including Kyong Hoon Ahn and Seung Woo Kim, to further advance research in insulin analogues and related fields.
Conclusion
Oh-Byung Kwon's contributions to the development of long-acting insulin analogues represent a significant advancement in diabetes care. His innovative approach not only enhances the effectiveness of insulin but also improves the daily lives of diabetic patients.